AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06293040
Drug: Placebo Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-alcoholic, placebo, flavored drink will be orally ingested.
Trial: NCT05027048
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm description above
Trial: NCT04828226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
Trial: NCT05901012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
Trial: NCT06365008
Drug: Sintilimab+irinotecan+leucovorin folinate+fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
Trial: NCT00001004
Drug: Tumor Necrosis Factor
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05116202
Drug: RO7247669 2100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
Trial: NCT05116202
Drug: RO7247669 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Trial: NCT06649409
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 200 mg single dose on Day 2
Trial: NCT05397171
Drug: AZD8853
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
Trial: NCT06418477
Drug: Dara-CyBorD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis.
Trial: NCT05512806
Drug: AZD5462
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD5462 orally.
Trial: NCT06575179
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group received volume-matched 0.9% saline infusions at identical rates.
Trial: NCT04319627
Drug: Rosuvastatin Calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
Trial: NCT04319627
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
Trial: NCT06621043
Drug: NTI164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.
Trial: NCT04709185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo at 23:00-24:00 the night before AVS
Trial: NCT04432090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
Trial: NCT04432090
Drug: Study Medication (MBX-2982)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
Trial: NCT05098067
Drug: Lactated Ringers, Intravenous
RxNorm normalized name: Lactated Ringers, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000cc once
Trial: NCT04995653
Drug: SER-155 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing with SER-155 placebo
Trial: NCT05845567
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
Trial: NCT06516055
Drug: S1B-408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with multiple monoamine activities
Trial: NCT06602271
Drug: PF614 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental oxycodone prodrug
Trial: NCT06602271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive medication
Trial: NCT04913337
Drug: NGM707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Trial: NCT06617728
Drug: Intervention 2: Intravenous (IV) Analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV medications used for pain control, including opioids and non-opioid analgesics.
Trial: NCT06579937
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During anesthesia induction, a bolus of equal 0.9% saline was administered intravenously.
Trial: NCT06315478
Drug: Clarithromycin 500Mg Tab
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
Trial: NCT06393257
Drug: Mucolytic
RxNorm normalized name: MUCOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucolytics were used in these patients.
Trial: NCT04889157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
Trial: NCT01273428
Drug: HP011-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06202664
Drug: Opioid Analgesic
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group of patient will receive general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia (Rise in Heart rate ± Blood Pressure by more than 20% from baseline).
Trial: NCT06623929
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
Trial: NCT05658055
Drug: probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China
Trial: NCT00000892
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06260046
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
Trial: NCT06260046
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
Trial: NCT06181305
Drug: estradiol valerate and letrozole
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hormone replacement therapy by estradiol valerate plus letrozole incorporation .
Trial: NCT06509451
Drug: Giomer pit and fissure sealant with etching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-PRG filler containig pit and fissure sealant with etching step
Trial: NCT04926844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
Trial: NCT05919992
Drug: Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7 in a total daily dose of 19.9mg
Trial: NCT05919992
Drug: Placebo 250 mg Tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
Trial: NCT05919992
Drug: Placebo (0,9% NaCl solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7
Trial: NCT06648876
Drug: YG1699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg qd for 8 days
Trial: NCT06648876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg qd for 8 days
Trial: NCT05737576
Drug: HR011408 injection; NovoRapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
Trial: NCT05737576
Drug: NovoRapid®；HR011408 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
Trial: NCT05737576
Drug: HR011408 injection; NovoRapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
Trial: NCT05737576
Drug: NovoRapid®；HR011408 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
Trial: NCT05737576
Drug: HR011408 injection; NovoRapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.
Trial: NCT05737576
Drug: HR011408 injection; NovoRapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.
Trial: NCT05554913
Drug: QL0911
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
Trial: NCT05554913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT05613608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm.
Trial: NCT05137847
Drug: Remitoro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion.
Trial: NCT04921527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg orally once daily
Trial: NCT05960227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250ml of saline 0,9% for 4 hours insusion.
Trial: NCT00072540
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05189093
Drug: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).
Trial: NCT04917458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
Trial: NCT05208294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive an inactive placebo capsule.
Trial: NCT06213896
Drug: Mydriatic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Trial: NCT06212271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description.
Trial: NCT05212701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
Trial: NCT03673748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous injection of saline solution without cells
Trial: NCT06204107
Drug: CKD-379(Empagliflozin+sitagliptin+metformin) Test drug
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once
Trial: NCT05458544
Drug: [177Lu]Ludotadipep 3.7 GBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection
Trial: NCT06431399
Drug: JLP-2004 qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
Trial: NCT04908215
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream base for dermal application containing no active agent
Trial: NCT05789589
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT).
Trial: NCT06620692
Drug: 5% GM-XANTHO [GM-XAN003]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% GM-XANTHO \[GM-XAN003\]
Trial: NCT06620692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo
Trial: NCT04634994
Drug: [F-18]SDM-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
Trial: NCT04358588
Drug: iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
Trial: NCT05726097
Drug: polyethylene glycol + ascorbic acid
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colonic preparation
Trial: NCT05839106
Drug: PM1032 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive PM1032 by intravenous administration.
Trial: NCT06395155
Drug: DHP2306R1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg per capsule, BID
Trial: NCT06395155
Drug: DHP2306R2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg per Tab, BID
Trial: NCT04955834
Drug: Tresiba®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long-acting insulin
Trial: NCT04585438
Drug: Diclofenac Potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug will be used as a transparent disc applied to the mucosa
Trial: NCT01609439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05703984
Drug: GC2129A(Period 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Trial: NCT05703984
Drug: GC2129A(Period 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Trial: NCT04507347
Drug: TRC041266
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC041266 sachet 1500 mg strengths
Trial: NCT04507347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC041266 sachet 1500 mg matching placebo
Trial: NCT06619301
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
Trial: NCT05368415
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
Trial: NCT05725252
Drug: NVP-2203-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of active comparator
Trial: NCT05936606
Drug: Tailored anti-platelet therapy
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
Trial: NCT01427816
Drug: KCT-0809
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01427816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04473820
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
Trial: NCT05252845
Drug: DHA-PIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
Trial: NCT04766996
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery
Trial: NCT04905277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo daily
Trial: NCT05451433
Drug: Saccharomyces Boulardii 250 MG
RxNorm normalized name: Saccharomyces boulardii 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normagut capsule twice a day
Trial: NCT05451433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule twice a day
Trial: NCT04504825
Drug: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to institutional standard of care.
Trial: NCT05806567
Drug: UGT1A1 victim drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral